Radioimmunotherapy might be useful as an initial and standalone treatment for follicular non-Hodgkin's lymphoma, according to a phase 2 study. The study, by Christian Scholz, MD, and colleagues from ...

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard. This research, ...

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in ...

Results from a Phase 1 clinical trial for a cancer therapy show the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this ...

With lower toxicity and equal efficacy, radioimmunotherapy is a better option than autologous stem cell transplant (ASCT) for relapsed /refractory follicular lymphoma consolidation, new data show.

Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal Cytogenetics: A Study of the Acute Myeloid Leukemia ...

A major advance in cancer therapy—high dose radioimmunotherapy—resulted in long-term remission for persons with mantle cell lymphoma. This often-fatal form of Non-Hodgkin’s Lymphoma (NHL) has a mean ...

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear ...

Radioimmunotherapy, targeting the CD20 antigen, in B-cell lymphoma has clearly demonstrated efficacy and tolerability over the preceding 15 years. As a result, two products are available with Food and ...

Scientists have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that selectively target and destroy microbial and HIV-infected cells. The experimental treatment -- ...

February 14, 2009 — (BRONX, NY) — Scientists at Albert Einstein College of Medicine of Yeshiva University have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that ...